Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... BM samples. Results TP53 mutations with a median clone size of 11% (range, 1% to 54%) were detected in 10 patients (18%) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... bone marrow microenvironment and the malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... In del(5q) patients, lenalidomide suppresses the clone by inhibiting the nuclear sequestration of the haplodeficient cell ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

    ... has a progressively cumulative effect on the MDS clone and support the value of maintenance therapy. Prolonged survival was ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia

    ... of a paroxysmal nocturnal hemoglobinuria clone (P=0.01) and a pretreatment absolute reticulocyte count ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

    ... a glycosylphosphatidylinositol-anchor protein-deficient clone was detected in 83 (40%) patients pre-treatment, and the median clone size was 9.7% (interquartile range 3.5-29). In patients without a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Loss of expression of neutrophil proteinase-3: a contributory factor in thrombotic risk in paroxysmal nocturnal hemoglobinuria.

    ... with a decrease in plasma proteinase 3 levels, clone size and history of thrombosis . In addition, we found that ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia.

    ... Twenty-seven patients with AA and a detectable PNH clone were monitored for a median of 5.7 years (range1.5 to 11.5 years). ... The erythrocyte and granulocyte PNH clone sizes were measured using flow cytometry and analyzed via CellQuest ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing

    ... were replaced by new clones, in 17.3% the same clone was present before HCT and at relapse, and in 9.7%, no abnormalities ...

    Research Article last updated 06/03/2015 - 12:48pm.

  10. David Araten, MD

    ... in PNH includes the  expansion of an abnormal stem cell clone in the bone marrow (called clonal expansion) which can by itself ... a very large percentage of the patient's blood cells. This clone has as its feature the presence of a mutation in a gene called ...

    Grant Recipient last updated 11/30/2016 - 10:51am.